Transcatheter closure of atrial septal defects

Babic, UrosU.; Grujicic, Sreten; Djurisic, Zoran; Vučinić, Marijana

doi:10.1016/0140-6736(90)92122-x

Cited by 20 publications

(8 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The origins of transcatheter ASD repair can be traced back to King's report of non-operative ASD closure during cardiac catheterization in 1976 [59] . Formal development of a device for ASD, however, is attributed to the Atrial Septal Defect Occluding System (ASDOS) submitted by Babic et al in 1990 [60] . Though successive iterations made the device more user friendly and showed early promise, the ASDOS was abandoned in 2001 with the development of newer generations of transcatheter devices.…”

Section: Transcatheter Devices Available Today For Closure Of Secundumentioning

confidence: 99%

Atrial septal defect repair in the age of transcatheter devices

Zimmermann¹,

Hussain²,

Worku³

et al. 2019

View full text Add to dashboard Cite

The aim of this review is to discuss the management of atrial septal defects (ASD) in the adult patient paying special attention to the elderly population and the most recent transcatheter advancements. ASDs are characterized by the following categories: ostium secundum, ostium primum, sinus venosus, and coronary sinus defects; though multiple defects may exist concurrently. Intervention for closure of ASDs are indicated with the development of right ventricular volume overload, or in the clinical context of paradoxical embolic stroke. Previously, there was significant disagreement regarding the timing of ASD closure in adult patients, but there is now general consensus that adult patients with clinical evidence of right ventricular overload should undergo closure of ASDs at the time of presentation. The present review describes the typical presentation of patients with symptomatic ASD's, medical management, and whether surgical or percutaneous approach should be pursued. We will also discuss other important considerations for patient selection and potential early and late complications of transcatheter ASD closure such as congestive heart failure, device embolization, and tissue erosion. At the time of this writing, there are currently three FDA-approved devices for percutaneous VSD closure including the Amplatzer TM Septal Occluder (ASO, St. Jude Medical, St. Paul, MN), Gore HELEX TM Septal Occluder (W.L. Gore and Associates, Newark, NJ), and Gore CARDIOFORM TM Septal occluder (GCSO, W.L. Gore and Associates, Newark, NJ) devices. Many premarket approvals were granted for devices that never went to market due to poor investigational study performance. Likewise, the HELEX device has since been discontinued upon bringing the GCSO device to market. We will focus primarily on the ASO device with a brief review of current investigations into the GCSO device, both of which carry an indication for closure small to medium sized ASDs in the ostium secundum position. Additionally, this review covers the safety of transcatheter closure of ASDs with currently available devices, review studies associated with devices available outside the United States, and perioperative considerations for transcatheter Page 2 of 18 Zimmermann et al. Vessel Plus 2019;3:31 I http://dx.intervention. Obstacles to device employment and countermeasures to overcome operational challenges will also be discussed. To this end, variations or similarities of currently approved devices will be emphasized throughout this discussion where possible. Lastly, we will offer insights into device evolution trends with the expectation of new device developments on the horizon. We will briefly discuss up and coming areas of active research, including the emerging fields of novel biomaterials and gene therapy. MORPHOLOGY AND CLINICAL FEATURES OF ASDS Location, Morphology, and suitability for surgery vs. transcatheter interventionIt is important to note that morphological variations of different types of ASDs, which determines whether a particular defect is amenabl...

show abstract

Section: Transcatheter Devices Available Today For Closure Of Secundumentioning

confidence: 99%

Atrial septal defect repair in the age of transcatheter devices

Zimmermann¹,

Hussain²,

Worku³

et al. 2019

View full text Add to dashboard Cite

show abstract

“…In 1990, Babic et al developed a European ASD closure device and named it the Atrial Septal Defect Occluding System (ASDOS) [28]. After several modifications of the original device, an updated prototype was licensed in 1994.…”

Section: Atrial Septal Defect Occluding Systemmentioning

confidence: 99%

Historical developments of atrial septal defect closure devices: what we learn from the past

Nassif

Abdelghani

Bouma

et al. 2016

Expert Review of Medical Devices

View full text Add to dashboard Cite

Introduction: Since King and Mills' pioneering work in percutaneous closure devices of secundum atrial septal defects (ASD) four decades ago, developments in device shape, material and implantation technique led to adoption of percutaneous ASD closure as current treatment of choice. Not only was the feasibility of such a percutaneous procedure tested altogether, but pursuing the ideal device in terms of safety and efficacy became priority. Areas covered: In this review we present the historical development of ASD devices in design, material and technique with clinical data, and provide the future perspectives in percutaneous ASD closures. Expert opinion: An 'ideal device' requires complete defect closure with negligible risk of complications using a safe, straightforward delivery technique with repositioning and retrieving properties. Some of the devices currently at hand come close to fulfilling these criteria, however none seem to provide those prerequisites completely. By understanding how challenges in device development were overcome in the past, new insights into future improvements are given. ARTICLE HISTORY

show abstract

“…This is a proposal for a simple and safe procedure that requires 20–30 minutes on the catheterization table and 18–36 hours in the hospital (including day‐one follow‐up). The steps of the procedure are the same for most devices that are currently used (e.g., Amplatzer 43 , CardiaStar 13 , CardioSeal‐Starflex 5 , 8 ) but not for older devices that were used earlier in this series (e.g., AngelWings 44 , ASDOS 45 , Buttoned Device 46 ).…”

Section: Technique For Transcatheter Pfo‐closurementioning

confidence: 99%

Indication and Techniques of Transcatheter Closure of Patent Foramen Ovale

Schräder¹

2003

J Interven Cardiology

View full text Add to dashboard Cite

A potential causal relationship of a patent foramen ovale (PFO) and a stroke was first suggested by Cohnheim in 1877.1 Today, this correlation is generally accepted. However, there is still no "gold standard" for the treatment of patients with presumed paradoxical embolism. This article reviews the epidemiology of and the diagnostic methods for PFO, the clinical relationship between PFO and cerebral ischemia, as well as indications and techniques for transcatheter closure of PFO. In the author's opinion, transcatheter PFO closure represents an elegant management for selected patients at risk.

show abstract

Transcatheter closure of atrial septal defects

Cited by 20 publications

References 3 publications

Atrial septal defect repair in the age of transcatheter devices

Atrial septal defect repair in the age of transcatheter devices

Historical developments of atrial septal defect closure devices: what we learn from the past

Indication and Techniques of Transcatheter Closure of Patent Foramen Ovale

Contact Info

Product

Resources

About